NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel therapies for intracranial malignancies, including glioblastoma and brain metastases.

• Lead products are NEO100 (intranasal perillyl alcohol) and NEO212 (oral/intranasal temozolomide conjugate), targeting brain cancers and other CNS disorders.

• NEO100 is in Phase IIa trials for glioma and meningioma; NEO212 is in Phase I/II for brain tumors and metastases.

• Proprietary drug delivery methods aim to bypass the blood-brain barrier, enhancing CNS drug penetration.

• Recent acquisition of AI-driven drug discovery and 3D bioprinting platforms to accelerate R&D and expand pipeline.

Financial performance and metrics

• No commercial product revenue; minimal revenue ($39,990 for nine months ended Sept 30, 2025) from humanitarian use.

• Net loss of $46.6M for nine months ended Sept 30, 2025, and $11.9M for year ended Dec 31, 2024.

• Accumulated deficit of $97.2M as of Sept 30, 2025.

• Cash balance of $1.5M as of Sept 30, 2025; substantial doubt about ability to continue as a going concern.

• Ongoing reliance on equity and debt financings; recent private placements and equity purchase agreements raised over $10M.

Use of proceeds and capital allocation

• Company will not receive proceeds from selling stockholders' sales; will receive proceeds only from warrant exercises, to be used for general corporate purposes.

• Recent capital raises used to settle short-term debt and support ongoing clinical trials.